Efficacy and Safety of LB1410 Plus Lenvatinib With or Without LB4330 in Advanced Recurrent/Metastatic Cervical Cancer

NCT07177716 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Cervical Cancer

Interventions

BIOLOGICAL: LB1410
BIOLOGICAL: LB4330
DRUG: Lenvatinib

Sponsor

L & L Bio Co., Ltd., Ningbo, China